Apelin has inhibitory effect of endothelium-independent relaxation in the human internal mammary artery

Aim: Apelin has important effects on the circulatory system and heart. The main aim of this study was to investigate the effectsof apelin-13 on the contraction induced by norepinephrine (NE), and the endothelium-independent relaxation induced by sodiumnitroprusside (SNP) in human internal mammary artery (IMA) obtained from patients undergoing coronary artery bypass grafting(CABG) surgery.Material and Methods: IMA rings, obtained from patients undergoing CABG surgery, were suspended in isolated tissue bathscontaining Krebs-Henseleit solution, which were continuously gassed with 95% O2 and 5% CO2 at 37°C.Results: The IMA rings were pre-contracted with increasing concentrations of norepinephrine (NE 10-9–10-4 mol/l) and theendothelium-independent relaxation responses to sodium nitroprusside (SNP) were studied. Apelin-13 (10 μM) caused a dosedependentrelaxation in NE pre-contracted IMA rings. Apelin also facilitated the endothelium-independent relaxation induced bySNP.Conclusion: According to the results, apelin facilitated the endothelium-independent relaxation and inhibited the contractile activityof IMA. These results suggest that apelin may be a physiological agent against the deterioration of vascular elasticity caused byendothelial damage especially in atherosclerotic cardiac patients and hypertensive patients.

PDF

___

1. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251:471-6.
2. Lu L, Wu D, Li L, et al. Apelin/APJ system: A bifunctional target for cardiac hypertrophy. Int J Cardiol 2017;230:164-70.
3. Medhurst AD, Jennings CA, Robbins MJ, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 2003;84:1162-72.
4. Huang Z, Wu L, Chen L. Apelin/APJ system: A novel potential therapy target for kidney disease. J Cell Physiol 2018;233:3892-900.
5. Kawamata Y, Habata Y, Fukusumi S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001;1538:162-71.
6. Liu J, Liu M, Chen L. Novel pathogenesis: regulation of apoptosis by Apelin/APJ system. Acta Biochimt Biophys Sin (Shanghai) 2017;49:471-8.
7. Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000;74:34-41.
8. Masri B, Knibiehler B, Audigier Y. Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal 2005;17:415-26.
9. Yamaleyeva LM, Shaltout HA, Varagic J. Apelin-13 in blood pressure regulation and cardiovascular disease. Curr Opin Nephrol Hypertens 2016;25:396-403.
10. Rostamzadeh F, Najafipour H, Yeganeh-Hajahmadi M, et al. Heterodimerization of apelin and opioid receptors and cardiac inotropic and lusitropic effects of apelin in 2K1C hypertension: Role of pERK1/2 and PKC. Life Sci 2017;191:24-33.
11. Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol 2006;553:222-8.
12. Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008;118:3343-54.
13. Hashimoto T, Kihara M, Imai N, et al. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol 2007;171:1705-12.
14. Li F, Li L, Qin X, et al. Apelin-induced vascular smooth muscle cell proliferation: the regulation of cyclin D1. Front Biosci 2008;13:3786-92.
15. Yu XH, Tang ZB, Liu LJ, et al. Apelin and its receptor APJ in cardiovascular diseases. Clin Chim Acta 2014;428:1-8.
16. Reaux A, De Mota N, Skultetyova I, et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem 2001;77:1085-96.
17. Katugampola SD, MacGuire JJ, Mathewson SR, et al. (125I)-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001;132:1255-60.
18. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide 2001;5:88-97.
19. Szokodi I, Tavi P, Földes G, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002;91:434-40.
20. Jia YX, Lu ZF, Zhang J, et al. Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides 2007;28:2023-9.
21. Koike R, Suma H, Kondo K, et al. Pharmacological response of internal mammary artery and gastroepiploic artery. Ann Thorac Surg 1990;50:384-6.
22. Burma O, Ozcan M, Kacar E, et al. In vitro effects of sodium nitroprusside and leptin on norepinephrine-induced vasoconstriction in human internal mammary artery. Cardiovascular J Afr 2015;26:4-7.
23. Mendonça L, Mendes-Ferreira P, Bento-Leite A, et al. Angiotensin-(1–7) modulates angiotensin II-induced vasoconstriction in human mammary artery. Cardiovasc Drugs Ther 2014;28:513-22.
24. O’Rourke ST, Vanhoutte PM, Miller VM. Vascular Pharmacology. In: Creager MA, Dzau VJ, Loscalzo J, eds. Vascular Medicine: A Companion to Braunwald’s Heart Disease. 3rd edition. Philadelphia: Saunders/Elsevier; 2006. p. 71-100.
25. Maguire JJ, Kleinz MJ, Pitkin SL, et al. (Pyr1)apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 2009;54:598-604.
26. Mughal A, Sun C, O’Rourke ST. Activation of large conductance, calcium-activated potassium channels by nitric oxide mediates apelin-induced relaxation of isolated rat coronary arteries. J Pharmacol Exp Ther 2018;366:265-73.
27. Busch R, Strohbach A, Pennewitz M, et al. Regulation of the endothelial apelin/APJ system by hemodynamic fluid flow. Cell Signal 2015;27:1286-96.